Metirosine
From Wikipedia, the free encyclopedia
Metirosine
|
|
Systematic (IUPAC) name | |
2-amino-3-(4-hydroxyphenyl)-2-methyl-propanoic acid | |
Identifiers | |
CAS number | |
ATC code | C02 |
PubChem | |
Chemical data | |
Formula | C10H13NO3 |
Mol. mass | 195.215 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | 3.4–3.7 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Metirosine (α-Methyltyrosine, AMPT) is an antihypertensive drug. It inhibits the enzyme tyrosine hydroxylase and, therefore, catecholamine synthesis, which consequently depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body.
[edit] Clinical use
Metirosine is used in the treatment of phaeochromocytoma. It is contra-indicated for the treatment of essential hypertension. However it is now rarely used in medicine, and its main use is in scientific research, to investigate the effects of catecholamine depletion on behaviour.[1]
[edit] See Also
[edit] References
- ^ O'Leary OF, Bechtholt AJ, Crowley JJ, Hill TE, Page ME, Lucki I. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology (Berlin). 2007 Jun;192(3):357-71. PMID 17318507
|